The short verdict
Wegovy suits most men who want semaglutide for weight loss. It is the FDA-approved product, made to a fixed standard, delivered by a pen that clicks to the right dose, and backed by its own large trials. Compounded semaglutide now fits a much smaller group: a man whose clinician documents a specific medical reason he cannot use the approved product, such as a reaction to an inactive ingredient.
That is a real shift from 2023 and 2024, when compounded versions were sold widely because the brand drug was in short supply. If you started on a compounded vial during those years, it helps to understand what changed before your next refill.
What changed in 2025
The change came from the FDA’s drug shortage list. On February 21, 2025, the agency announced that the shortage of injectable semaglutide was resolved, and the temporary leeway for compounders began to wind down, as the FDA’s compounding policy update explains. For state-licensed 503A pharmacies that grace period is over, and larger 503B outsourcing facilities had until May 22, 2025. Tirzepatide went through the same process a few months earlier.
What remains is the normal rule. A compounder may not make what the FDA calls “essentially a copy” of a commercially available drug, meaning the same active ingredient in the same or an easily substituted strength. The exception is a change that a clinician determines and documents will make a significant difference for an identified individual patient. Our page on whether compounded semaglutide is legal in 2026 walks through that test in plain terms.
Compounded semaglutide and Wegovy side by side
| Compounded semaglutide (2026) | Wegovy | |
|---|---|---|
| FDA status | Not approved; the finished product is not reviewed by the FDA | Approved for weight reduction, heart risk reduction and a form of fatty liver disease |
| Who can get it | Individual patients with a documented clinical need for a difference | Adults who meet the label criteria, plus some teens |
| Active ingredient | Should be semaglutide base; salt forms are a warning sign | Semaglutide |
| Dose steps | Set by the clinician and pharmacy, often drawn from a vial | 0.25, 0.5, 1, 1.7 and 2.4 mg weekly, with 7.2 mg for some adults |
| Device | Usually a vial and syringe | Prefilled pen, or a daily tablet |
| Trial evidence | Borrowed from the brand drug | Its own phase 3 trials |
| Adverse event reporting | 503A pharmacies are not required to report to the FDA | The manufacturer must report |
The Wegovy label lays out the steps: 0.25 mg weekly for four weeks, then 0.5, 1 and 1.7 mg, landing on 1.7 or 2.4 mg as the maintenance dose. A 2026 label update added 7.2 mg weekly for adults who have tolerated 2.4 mg for at least four weeks and still need more weight loss. Your provider sets the dose and the pace.
How each one is made and checked
Wegovy is manufactured under the FDA’s rules for approved drugs, and its label, dose strengths and device were reviewed before it reached pharmacies. In the STEP 1 trial, adults on the 2.4 mg dose lost an average of 14.9% of body weight over 68 weeks, compared with 2.4% on placebo. A compounded version has no trial of its own; it relies on that evidence and on the quality of the pharmacy that made it.
The FDA has flagged two specific problems with compounded products. First, some pharmacies have used semaglutide sodium or semaglutide acetate. The FDA says these salt forms are different active ingredients from the one in approved products, and it knows of no lawful basis for compounding with them. Second, the agency has received reports of dosing errors, some needing hospital care, when patients measured their own doses from multi-dose vials.
Products labeled “for research use only” are a separate issue: they are not compounded medicines at all. Our article on the FDA warning about research-use semaglutide explains why.
Side effects: same molecule, different risks
The molecule behaves the same way whichever product it comes in. Nausea, vomiting, diarrhea, constipation and belly pain are common while the dose rises. Less common but serious problems include pancreatitis, gallbladder disease and kidney strain from dehydration. Semaglutide also carries a boxed warning about thyroid C-cell tumors seen in rodents, and it is not used in men with a personal or family history of medullary thyroid cancer or MEN 2.
What differs is precision. A pen delivers a fixed amount. A vial depends on the concentration printed on the label and on drawing the right number of units, which is where the FDA’s dosing-error reports come from. Severe belly pain that does not ease, with or without vomiting, needs urgent care the same day, not a scheduled visit.
Cost and convenience
Price is the reason most men asked about compounding in the first place. As of October 2026, NovoCare’s self-pay page lists Wegovy pens at $349 a month for the 0.25 mg through 2.4 mg doses and $399 a month for the 7.2 mg dose, with a $199 introductory price on the first two fills of the starting doses through December 31, 2026. Those figures are the manufacturer’s, can change, and do not include the medical care around the medicine.
A compounded preparation’s price depends on the pharmacy, the dose and the documentation behind it. A lower monthly figure is not, by itself, a documented clinical need. For a fuller breakdown of what drives the numbers, see our guide to compounded semaglutide cost in 2026, and if you are weighing brand names, our comparison of Ozempic and Wegovy covers how the two approvals differ.
How Ultimate Male helps you choose
Ultimate Male does not promise a compounded product, and it does not treat compounding as a discount option. The process starts with a free 10-minute phone call, then same-day labs at our San Gabriel or Downey clinic, with results in 24 to 48 hours. A PA-C or MD reviews those results with you, along with the exact label of anything you have been injecting, and explains which product they recommend and why.
If you are already on semaglutide from another source, bring the vial or a photo of the pharmacy label. The provider can then work out an equivalent starting point and a monitoring plan. Ultimate Male is a direct-pay clinic with itemized receipts for FSA and HSA accounts, financing options and no published prices, so you get a quote before you commit. Learn more about the medical weight loss program or start with the free call.
